Clinical Trials · NCT00149188

Somatuline Autogel: Acromegaly Self/Partner Injection Study

CompletedPhase 4Lanreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Ipsen
Enrollment
30
Start date
Feb 2004
Locations
10 sites, United Kingdom
Primary endpoint
To assess the ability of patients or their partners to perform unsupervised Somatuline Autogel injections.
View Lanreotide compound reference